Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2014/12/02
-
Journal
-
Indian UGC (journal)
-
Refrences64
-
Citations125
-
Magdalena Mazagova Department of MedicineUniversity of CaliforniaSan DiegoLa JollaCaliforniaUSA
-
Lirui Wang Department of MedicineUniversity of CaliforniaSan DiegoLa JollaCaliforniaUSADepartment of Medicine, VA San Diego Healthcare SystemSan DiegoCaliforniaUSA
-
Andrew T. Anfora Genomics Institute of the Novartis Research FoundationSan DiegoCaliforniaUSA
-
Max Wissmueller Department of MedicineUniversity of CaliforniaSan DiegoLa JollaCaliforniaUSA
-
Scott A. Lesley Genomics Institute of the Novartis Research FoundationSan DiegoCaliforniaUSA
-
Yukiko Miyamoto Department of MedicineUniversity of CaliforniaSan DiegoLa JollaCaliforniaUSA
-
Lars Eckmann Department of MedicineUniversity of CaliforniaSan DiegoLa JollaCaliforniaUSA
-
Suraj Dhungana Systems and Translational ScienceRTI InternationalResearch Triangle ParkNorth CarolinaUSA
-
Wimal Pathmasiri Systems and Translational ScienceRTI InternationalResearch Triangle ParkNorth CarolinaUSA
-
Susan Sumner Systems and Translational ScienceRTI InternationalResearch Triangle ParkNorth CarolinaUSA
-
Caroline Westwater Department of Oral Health SciencesMedical University of South CarolinaCharlestonSouth CarolinaUSA
-
David A. Brenner Department of MedicineUniversity of CaliforniaSan DiegoLa JollaCaliforniaUSA
-
Bernd Scmiabl Department of MedicineUniversity of CaliforniaSan DiegoLa JollaCaliforniaUSADepartment of Medicine, VA San Diego Healthcare SystemSan DiegoCaliforniaUSA
Cite
Mazagova, Magdalena, et al. “Commensal Microbiota Is Hepatoprotective and Prevents Liver Fibrosis in Mice”. The FASEB Journal, vol. 29, no. 3, 2014, pp. 1043-55, https://doi.org/10.1096/fj.14-259515.
Mazagova, M., Wang, L., Anfora, A. T., Wissmueller, M., Lesley, S. A., Miyamoto, Y., Eckmann, L., Dhungana, S., Pathmasiri, W., Sumner, S., Westwater, C., Brenner, D. A., & Scmiabl, B. (2014). Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. The FASEB Journal, 29(3), 1043-1055. https://doi.org/10.1096/fj.14-259515
Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. The FASEB Journal. 2014;29(3):1043-55.
Journal Categories
Science
Biology (General)
Science
Biology (General)
Cytology
Science
Chemistry
Organic chemistry
Biochemistry
You May Also Like
- Hsp70 chaperones: Cellular functions and molecular mechanism
- Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism
- Current knowledge on exosome biogenesis and release
- Immune checkpoint inhibitors: recent progress and potential biomarkers
- ROS in cancer therapy: the bright side of the moon
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Increase in terminal restriction fragments of Bacteroidetes‐derived 16S rRNA genes after administration of short‐chain fructooligosaccharides | Applied and Environmental Microbiology |
| 2006 | |
| Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis | 2010 | |||
| Intestinal permeability is increased in patients with advanced cirrhosis | 2003 | |||
| TLR4 enhances TGF-β signaling and hepatic fibrosis | Nature Medicine |
| 1,406 | 2007 |
LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice | American Journal of Physiology-Gastrointestinal and Liver Physiology |
| 92 | 2006 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases | Seminars in Immunology |
| 2024 | |
Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials | BMC Medicine |
| 1 | 2024 |
Liver cirrhosis and complications from the perspective of dysbiosis | Frontiers in Medicine |
| 1 | 2024 |
CD14 is not required for carbon tetrachloride‐induced hepatic inflammation and fibrosis with or without lipopolysaccharide challenge | Journal of Cellular Physiology |
| 2023 | |
| Mechanisms Behind NAFLD: a System Genetics Perspective | Current Atherosclerosis Reports |
| 2023 |
Citations Analysis
The category
Medicine: Medicine (General) 50
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Neue Therapieoptionen für die Leberfibrose and was published in 2015. The most recent citation comes from a 2024 study titled Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials. This article reached its peak citation in 2021, with 20 citations. It has been cited in 87 different journals, 36% of which are open access. Among related journals, the Hepatology cited this research the most, with 6 citations. The chart below illustrates the annual citation trends for this article.